Patients diagnosed with a renal mass smaller than 3 cm have a variety of treatment options, including surgical options, ablative therapies and active surveillance. Studies have shown that about one in five of these lesions is benign and the majority of tumors that turn out to be renal cancers are low grade and unlikely to metastasize.
Four experts will debate the best treatment approach for a 3 cm asymptomatic renal mass in an adult male during Sunday afternoon’s Prime Time plenary session in the Esplanade Ballroom at Moscone South. Ralph V. Clayman, MD, professor of Urology at the University of California, Irvine, will moderate the 30-minute debate, titled Crossfire: Controversies in Urology: Kidney Cancer.
Ketan Badani, MD, professor of Urology at Icahn School of Medicine at Mount Sinai Hospital, and Craig Rogers, MD, FACS, Director of Renal Surgery and Urologic Oncology at the Vattikuti Urology Institute at Henry Ford Hospital, will make the case for surgical intervention. Jaime Landman, MD, Chair and professor in the Department of Urology at the University of California, Irvine, and R. Houston Thompson, MD, professor of Urology at the Mayo Clinic, will argue for less invasive approaches like renal biopsy, active surveillance and thermal ablation.
In the past, AUA recommendations have noted that tumor ablation was only appropriate in patients that were too high risk for surgical resection. These guidelines have been expanded to include thermal ablation as an alternative treatment.
“I hope attendees leaving this session will, from this point onward, consider whether they should actively surveil a small renal mass or biopsy it before proceeding to a surgical solution,” Dr. Clayman said. “Every problem you see as a urologist is not an indication for surgery.”